ZUPLENZ
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZUPLENZ (ZUPLENZ).
Competitive serotonin 5-HT3 receptor antagonist; acts centrally on the chemoreceptor trigger zone and peripherally on GI vagal nerve terminals to inhibit emesis.
| Metabolism | Hepatic, primarily via CYP3A4, CYP1A2, and CYP2D6; first-pass metabolism. |
| Excretion | Renal 70% unchanged, fecal 20% (including biliary metabolites), 10% metabolized |
| Half-life | Terminal elimination half-life 3.5 hours; in hepatic impairment increases to 7-9 hours |
| Protein binding | 60% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 2.4 L/kg; indicates extensive tissue distribution |
| Bioavailability | Oral: 65% (due to first-pass metabolism); IV: 100% |
| Onset of Action | Oral: 30-60 minutes; IV: within 5 minutes |
| Duration of Action | 8-12 hours; prolonged in renal impairment |
8 mg administered intraorally as a single dose 1 hour before chemotherapy; may repeat once if vomiting occurs within 30 minutes after initial dose.
| Dosage form | FILM |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min, reduce dose to 4 mg intraorally once daily. |
| Liver impairment | Child-Pugh Class A or B: No dose adjustment. Child-Pugh Class C: Maximum daily dose of 8 mg intraorally, administered as a single dose. |
| Pediatric use | Children aged 6 months to 12 years: 0.15 mg/kg/dose (maximum 8 mg per dose) intraorally 30 minutes before chemotherapy; may repeat once after 4 hours if vomiting persists. |
| Geriatric use | No specific dose adjustment recommended; however, elderly patients may have reduced renal function, so consider monitoring renal function and adjust dose if GFR <30 mL/min. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ZUPLENZ (ZUPLENZ).
| Breastfeeding | Ondansetron is excreted in human milk with a milk-to-plasma ratio of approximately 1.0. Limited data suggest no adverse effects in breastfed infants. Caution is advised due to potential adverse effects (e.g., diarrhea) in infants. The benefits of breastfeeding generally outweigh risks. |
| Teratogenic Risk | First trimester: Data from human pregnancies are inadequate; animal studies have not shown teratogenic effects. Second and third trimesters: No evidence of fetal harm. Zuplenz (ondansetron) is classified as FDA Pregnancy Category B; however, recent studies suggest a small increased risk of oral clefts when used in the first trimester. Overall risk is considered low. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to ondansetron or any component; concomitant use with apomorphine.
| Precautions | Serotonin syndrome (especially when used with other serotonergic drugs); QT prolongation (avoid in patients with pre-existing QT prolongation or electrolyte abnormalities); acute dystonic reactions; masked paralytic ileus. |
Loading safety data…
| Fetal Monitoring | No specific maternal-fetal monitoring required beyond standard prenatal care. Monitor for maternal adverse effects such as QT prolongation, serotonin syndrome, or hypersensitivity. |
| Fertility Effects | No known effects on fertility based on animal studies; human data are insufficient. |